they are inhibited by the PTH antagonist [8norleucyl, "8nor-leucyl, 3tyrosinyl]PTH (3-34)amide (4, 5) . It is therefore assumed that the clinically relevant hypercalcemia is also produced by human humoral hypercalcemia factors (HCF) interaction with the PTH receptor. The recent elucidation ofthe sequence of the HCF (1, 6) made it possible to synthesize a fragment of the factor and examine directly its effects on PTH-responsive cells. ROS 17/2.8 and other cells of the osteoblastic lineage possess adenylate cyclase-coupled FTH receptors which may be involved in the bone resorptive action of PTH (7) . It has also been suggested that not all PTH effects are produced by adenylate cyclase stimulation, and that receptor-mediated changes in intracellular calcium (8) may be involved in bone resorption (9) . Although it has been demonstrated that the tumor-derived factors stimulate adenylate cyclase in osteoblastic cells, it has not been shown that they produce biological effects similar to those of PTH. In view of these possibilities, we examined the nature and relative efficacy of PTH and HCF City, CA). The peptide was then purified by gel filtration followed by preparative HPLC. The peptide, after chemical analysis, was found to be authentic and of high purity (> 99%) by HPLC, amino acid analysis, Edman sequence analysis, fast atom bombardment mass spectrometry, and proton nuclear magnetic resonance (16) .
Results Fig. 1 shows dose-dependent stimulation of cAMP accumulation by HCF and PTH in cells grown in the presence of dexamethasone and the respective controls. The effective concentration (EC)50 for adenylate cyclase stimulation was the same (-1 nM) for either peptide with or without dexamethasone treatment. However, in the absence of dexamethasone, HCF was slightly more stimulatory compared with PTH. In the presence of dexamethasone, this difference disappeared and the dose-response curves of the two peptides overlapped (Fig.  1 B) . The growth inhibitory effects of HCF and PTH were dose dependent (Fig. 3) . In the absence of dexamethasone, neither peptide inhibited growth of ROS 17/2.8 cells. In the presence ofdexamethasone both peptides inhibited growth with an EC50 of -0.1 nM.
We next compared the effects of HCF and PTH on AP activity (Fig. 4) . Both HCF and PTH inhibited AP activity in a dose-dependent manner by 70% in the absence of dexametha- sensitive rat osteosarcoma ROS 17/2.8 cells were also produced by 1-34 HCF. Moreover, the dose-response curves generated for the postreceptor effects were virtually overlapping in all instances for both synthetic peptides used in this study.
The HCF preparation was slightly more potent in stimulating adenylate cyclase, as previously observed by Moseley et al. (1) (19) and the activation of protein kinase isoenzyme I is believed to play a role in cell proliferation (20) . PTH was shown to stimulate predominantly the isoenzyme I of cAMP-dependent protein kinase (21) and to inhibit growth (22) in the osteogenic sarcoma cell line UMR 106.
AP is a major osteoblastic marker. The level ofthis enzyme in ROS 17/2.8 cells was shown to increase with dexamethasone treatment and decrease in response to PTH (10) . Northern analysis indicated that these changes were accompanied by parallel changes in AP mRNA. HCF produced effects identical to PTH on AP activity and AP mRNA. PTH and HCF inhibited AP to the same extent (-70-80%) and with the same EC50 in the presence and absence of dexamethasone. This is consistent with previous findings showing that glucocorticoid potentiation of adenylate cyclase stimulation and of other PTH effects in calvarial osteoblasts (23) and osteosarcoma cells (24) did not alter hormone affinity.
In conclusion, we have shown that a chemically synthesized fragment of HCF produces a profile of postreceptor effects identical to PTH in ROS 17/2.8 cells. Furthermore, the potency of HCF across the spectrum of effects studied is comparable to PTH. These findings support the hypothesis that HCF produces PTH-like effects on bone and that these effects are mediated via interaction with the PTH receptor.
